When analyses were stratified by AD biomarker status, increases in IIV were associated with reductions in entorhinal [β = −0.509, p = 0.007; Overall model: R2 = 0.369, F (3,17) = 3.307, p = 0.045] and hippocampal CBF [β = −0.447, p = 0.055; Overall model: R2 = 0.208, F (3,17) = 1.488, p = 0.253] among individuals who were p-tau/Aβ+ (n = 21) (see Table 3). The gene discussed is MAPT; the disease is Alzheimer disease.